Ruthenium-enhanced curcumin derivatives target tumor growth and cancer-related inflammation in head and neck cancer models
Kateřina Veselá, Ameneh Tatar, Zdeněk Kejík, Nikita Abramenko, Robert Kaplánek, Petr Babula, Kateřina Kučnirová, Jan Hajduch, Pavel Martásek, Milan Jakubek · 2025
Read Ruthenium-enhanced curcumin derivatives target tumor growth and cancer-related inflammation in head and neck cancer models by Kateřina Veselá, Ameneh Tatar, Zdeněk Kejík, Nikita Abramenko, Robert Kaplánek, Petr Babula, Kateřina Kučnirová, Jan Hajduch, Pavel Martásek, Milan Jakubek (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12754617.txt.
Description
Kateřina Veselá and co-authors forged new drug candidates from a spice compound, in a 2025 study. Curcumin, the yellow heart of turmeric, fights both tumors and inflammation, but weakly. The team bonded it to the metal ruthenium, making two new complexes aimed at head and neck cancers. Such cancers often grow under steady inflammation fed by tobacco smoke and virus infection.
One complex killed and stalled cancer cells of both virus-linked and plain types. The other acted mainly on mouth cancer cells. Both slowed cell movement and cut the chemical signals that feed inflammation far better than curcumin alone. The authors see the pair as solo drugs or as helpers beside standard care.
Catalog record
| CREATOR | Kateřina Veselá, Ameneh Tatar, Zdeněk Kejík, Nikita Abramenko, Robert Kaplánek, Petr Babula, Kateřina Kučnirová, Jan Hajduch, Pavel Martásek, Milan Jakubek |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |